Chiusura precedente | 3,3000 |
Aperto | 3,3000 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 3,3000 - 3,3000 |
Intervallo di 52 settimane | 2,9900 - 4,4600 |
Volume | |
Media Volume | 0 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | 31 lug 2024 - 05 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the American Society of Nephrology (ASN) Kidney Week 2023 meeting to be held in Philadelphia, PA, November 1-5, 2023. XPHOZAH (tenapanor), discovered and developed by
WALTHAM, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today shared data on the investigational use of IBSRELA® (tenapanor) in pediatric patients via two poster presentations presented at the 2023 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, c
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of results from the T3MPO-3 long-term open-label safety trial of IBSRELA® (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in the Journal of Neurogastroenterology and Motility (JNM). The paper, title